Product Name:3-Amino-2-bromo-4-picoline

IUPAC Name:2-bromo-4-methylpyridin-3-amine

CAS:126325-50-6
Molecular Formula:C6H7BrN2
Purity:95%+
Catalog Number:CM102708
Molecular Weight:187.04

Packing Unit Available Stock Price($) Quantity
CM102708-100g in stock ɅƻɅ

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:126325-50-6
Molecular Formula:C6H7BrN2
Melting Point:-
Smiles Code:CC1=C(N)C(Br)=NC=C1
Density:
Catalog Number:CM102708
Molecular Weight:187.04
Boiling Point:308°C at 760 mmHg
MDL No:MFCD04112497
Storage:Keep in a tight container and store at 2°C~8°C

Category Infos

Pyridines
Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

Column Infos

Glecirasib
On January 20, Jacobio Pharma presents data of glecirasib in patients with pancreatic cancer and other solid tumors at the 2024 ASCO GI. For second-line and above KRAS G12C mutated pancreatic cancer patients, the confirmed objective response rate (cORR) was 41.9% and the disease control rate (DCR) was 93.5%. Glecirasib is a potential best-in-class KRAS G12C allosteric inhibitor with promising early clinical efficacy. Glecirasib can be used as monotherapy to treat non-small cell lung cancer, colorectal cancer and other solid tumors with the KRAS G12C mutation. Combinations of Glecirasib with SHP2i, EGFRi, or PD-1 antibodies is expected to have synergistic efficacy and overcome acquired drug resistance.